Departmental News


On November 18, 1999, the first transmyocardial revascularization (TMR) operation on Long Island was successfully performed by our Division of Cardiothoracic Surgery. This new approach to the treatment of coronary artery disease promises to offer an alternative to patients who do not respond to currently available forms of therapy, such as balloon angioplasty and coronary artery bypass grafting (CABG).

TMR involves use of a computer-controlled carbon dioxide laser to create new conduits for blood flow by boring small channels from the outside to the inside of the heart, specifically, the left ventricular cavity. These channels induce a natural process of healing called angiogenesis—that is, the growth of new blood vessels, which increase blood flow to feed oxygen-starved areas in the heart muscle.

Patients treated by TMR experience angina relief within weeks of sole therapy (TMR alone), or immediately when the technique is used in combination with CABG.

The first TMR operation on Long Island was performed by
Dr. Irvin B. Krukenkamp.

TMR has been studied extensively in experimental and clinical settings. The original investigational studies were conducted in the early 1970s. In recent years, nationally reported clinical studies indicate a lasting response at three years. When TMR is used in combination with CABG, three-year mortality rates are significantly reduced from about 12% to 4%.

Since TMR is performed on the beating heart without the use of cardiopulmonary bypass (CPB) via the heart-lung machine, this novel method of increasing blood flow to the heart may also be considered minimally invasive when used as sole therapy.

The adverse side effects associated with use of the heart-lung machine—which, during conventional CABG, takes over the stopped heart's work—are avoided. Patients do not experience the inflammatory response caused by CPB, which disrupts the body's physiologic balance.

TMR probably won't replace angioplasty or CABG surgery as the most common methods of treating coronary artery disease. These therapies have been proven over time to be safe, effective ways to restore blood flow to the heart muscle.

At present, the best candidates for TMR include patients who are high-risk candidates for a second bypass or angioplasty; patients whose blockages are too diffuse to be treated with bypass alone; and patients with heart transplants who develop atherosclerosis on the graft.

Since performing our first TMR operation, an increasing number of patients have been coming to Stony Brook for this treatment.

The Operation Itself

To perform TMR, the surgeon makes a limited incision on the left side of the chest and inserts a laser into the chest cavity. With the laser, the surgeon shoots holes through the heart's left ventricle in between heartbeats; the laser is fired when the chamber is full of blood so the blood can protect the inside of the heart.

The characteristics of laser energy make it an ideal tool to use. The channels can be made with little damage to surrounding tissue, and they can be made quickly.

From 15 to 30 channels, each a millimeter in diameter, are opened. Then the surgeon presses a finger on the holes on the outside of the heart. This seals the outer openings but lets the inner channels stay open to stimulate the growth of new blood vessels.

The operation takes about two hours to complete. The average hospital stay following the procedure ranges from two to seven days, depending on whether TMR is used as sole therapy (about seven days) or in combination with different methods of CABG surgery (about two to five days).

Currently, clinical trials are being conducted to evaluate the effectiveness of TMR used without CABG. If proven effective as sole therapy, this approach would offer an alternative form of treatment to those suffering from coronary artery disease, particularly those who otherwise would have no other options. Approval from the Food and Drug Administration will be sought if warranted by the results of these studies.

For consultations/appointments, please call our Division of Cardiothoracic Surgery at 631-444-1820.

Back to Departmental NewsReturn to Home Page